Immix Biopharma (IMMX) Debt to Equity (2020)
Quarterly results put Debt to Equity at -$0.12 for Q4 2020, changed N/A from a year ago — trailing twelve months through Dec 2020 was -$0.12 (changed N/A YoY), and the annual figure for FY2020 was -$0.12, changed.
Immix Biopharma has reported Debt to Equity over the past 1 years, most recently at -$0.12 for Q4 2020.
- Debt to Equity reached -$0.12 in Q4 2020 per IMMX's latest filing.
- Across five years, Debt to Equity topped out at -$0.12 in Q4 2020 and bottomed at -$0.12 in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 0.06 |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -0.12 |